India Liberalizes Foreign Investments But Will Money Flow?
This article was originally published in PharmAsia News
Following the easing of India’s foreign direct investment norms in the pharmaceutical sector, reforms are expected to buoy foreign capital inflows and investor sentiment, especially private equity, though some opponents claim it may potentially have a dire impact on India's future medicines security.
You may also be interested in...
China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.
The Fosun group led by its billionaire chair Guo Guangchang has snapped up the injectables firm Gland for around $1.26bn, the first mega Chinese buy in the Indian pharmaceutical space. The deal opens up many potential collaborative opportunities, though it remains to be seen how smoothly it sails through in the Indian regulatory maze.
India’s more muscular intellectual property protection policy is a good first step but the government will have to “walk the talk” to attract significant new investment from global pharmaceutical companies, say US experts. Implementation of the policy will be the key measure of its success, they say.